GlassScriptPhysician profile
Molly E Wiwi
NPI 1922519669
$2,806.23
in general payments reported to CMS, 2019-2025
33 companies · $1,802 in 2025
The $1,802 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,004 · 2025: $1,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,806.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $341.58 | 2024-2025 | Omnipod |
| Lilly USA, LLC | $202.66 | 2024-2025 | Zepbound, Mounjaro, Jardiance |
| Abbott Laboratories | $202.26 | 2024-2025 | Freestyle Libre 3, Afinion 2 |
| Xeris Pharmaceuticals, INC. | $200.18 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Recordati_rare_diseases_inc. | $165.75 | 2024-2025 | Isturisa, Signifor Lar |
| Amgen INC. | $163.04 | 2024-2025 | Evenity, Tepezza, Repatha |
| Dexcom, INC. | $156.75 | 2024-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $152.36 | 2024-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $135.62 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $114.40 | 2025 | Yorvipath |
| Novo Nordisk INC | $103.65 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.44 | 2024-2025 | Jardiance |
| Chiesi USA, INC. | $98.73 | 2024-2025 | Mycapssa |
| Novartis Pharmaceuticals Corporation | $79.69 | 2024-2025 | |
| Radius Health, INC. | $61.35 | 2024 | Tymlos |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $58.92 | 2024-2025 | Veozah |
| Abbvie INC. | $56.75 | 2024-2025 | |
| Cequr Corporation | $55.54 | 2024 | Cequr Simplicity |
| Sequel Med Tech, LLC | $50.13 | 2025 | Twiist |
| Medtronic, INC. | $42.70 | 2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals LP | $32.46 | 2024-2025 | Farxiga |
| Tandem Diabetes Care, INC. | $31.86 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $25.27 | 2025 | Strensiq |
| Ibsa Pharma INC. | $24.27 | 2025 | Licart, Flector, Tirosint |
| Aimmune Therapeutics, INC. | $23.48 | 2025 | Zenpep |
| Globus Medical, INC. | $22.56 | 2025 | Senza |
| Nevro Corp. | $17.59 | 2024 | Senza |
| Kyowa Kirin, INC. | $15.98 | 2025 | |
| Almatica Pharma LLC | $15.97 | 2024 | Teriparatide |
| Amneal Pharmaceuticals LLC | $15.92 | 2025 | Unithroid |
| Tolmar, INC. | $15.86 | 2025 | Jatenzo |
| Neurocrine Biosciences, INC. | $14.06 | 2024 | |
| Beta Bionics, INC. | $9.45 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Wiwi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.